Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Guido Tricot and Maurizio Zangari.

 
Connection Strength
  
 
 
8.674
  
  1. Zangari M, Terpos E, Zhan F, Tricot G. Impact of bortezomib on bone health in myeloma: a review of current evidence. Cancer Treat Rev. 2012 Dec; 38(8):968-80.
    View in: PubMed
    Score: 0.391
  2. Zangari M, Aujay M, Zhan F, Hetherington KL, Berno T, Vij R, Jagannath S, Siegel D, Keith Stewart A, Wang L, Orlowski RZ, Belch A, Jakubowiak A, Somlo G, Trudel S, Bahlis N, Lonial S, Singhal S, Kukreti V, Tricot G. Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. Eur J Haematol. 2011 Jun; 86(6):484-7.
    View in: PubMed
    Score: 0.375
  3. Zangari M, Yaccoby S, Pappas L, Cavallo F, Kumar NS, Ranganathan S, Suva LJ, Gruenwald JM, Kern S, Zhan F, Esseltine D, Tricot G. A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients. Haematologica. 2011 Feb; 96(2):333-6.
    View in: PubMed
    Score: 0.359
  4. Zangari M, Zhan F, Tricot G. Bone and paraproteinemias. Curr Opin Support Palliat Care. 2010 Sep; 4(3):195-9.
    View in: PubMed
    Score: 0.356
  5. Zangari M, Esseltine D, Cavallo F, Neuwirth R, Elice F, Burns MJ, Yaccoby S, Richardson P, Sonneveld P, Tricot G. Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients. Am J Hematol. 2007 Sep; 82(9):831-3.
    View in: PubMed
    Score: 0.289
  6. Zangari M, Elice F, Fink L, Tricot G. Hemostatic dysfunction in paraproteinemias and amyloidosis. Semin Thromb Hemost. 2007 Jun; 33(4):339-49.
    View in: PubMed
    Score: 0.284
  7. Zangari M, Cavallo F, Tricot G. Farnesyltransferase inhibitors and rapamycin in the treatment of multiple myeloma. Curr Pharm Biotechnol. 2006 Dec; 7(6):449-53.
    View in: PubMed
    Score: 0.275
  8. Zangari M, Yaccoby S, Cavallo F, Esseltine D, Tricot G. Response to bortezomib and activation of osteoblasts in multiple myeloma. Clin Lymphoma Myeloma. 2006 Sep; 7(2):109-14.
    View in: PubMed
    Score: 0.270
  9. Zangari M, Elice F, Tricot G. Immunomodulatory drugs in multiple myeloma. Expert Opin Investig Drugs. 2005 Nov; 14(11):1411-8.
    View in: PubMed
    Score: 0.255
  10. Zangari M, Barlogie B, Anaissie E, Saghafifar F, Eddlemon P, Jacobson J, Lee CK, Thertulien R, Talamo G, Thomas T, Van Rhee F, Fassas A, Fink L, Tricot G. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol. 2004 Sep; 126(5):715-21.
    View in: PubMed
    Score: 0.235
  11. Zangari M, Saghafifar F, Mehta P, Barlogie B, Fink L, Tricot G. The blood coagulation mechanism in multiple myeloma. Semin Thromb Hemost. 2003 Jun; 29(3):275-82.
    View in: PubMed
    Score: 0.216
  12. Zangari M, Barlogie B, Thertulien R, Jacobson J, Eddleman P, Fink L, Fassas A, Van Rhee F, Talamo G, Lee CK, Tricot G. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin Lymphoma. 2003 Jun; 4(1):32-5.
    View in: PubMed
    Score: 0.216
  13. Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A, Morris C, Fink L, Tricot G. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood. 2002 Aug 15; 100(4):1168-71.
    View in: PubMed
    Score: 0.204
  14. Mohan M, Kendrick S, Szabo A, Yarlagadda N, Atwal D, Pandey Y, Roy A, Parikh R, Lopez J, Thanendrarajan S, Schinke C, Alapat D, Sawyer J, Tian E, Tricot G, van Rhee F, Zangari M. Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood Adv. 2022 02 08; 6(3):808-817.
    View in: PubMed
    Score: 0.197
  15. Mohan M, Szabo A, Yarlagadda N, Gundarlapalli S, Thanendrarajan S, Kendrick S, Schinke C, Alapat D, Sawyer J, Tian E, Tricot G, van Rhee F, Zangari M. Persistent bone marrow minimal residual disease as a "high-risk" disease feature in multiple myeloma. Am J Hematol. 2021 09 01; 96(9):E341-E344.
    View in: PubMed
    Score: 0.189
  16. Zangari M, Berno T, Yang Y, Zeng M, Xu H, Pappas L, Tricot G, Kamalakar A, Yoon D, Suva LJ. Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors. Bone. 2014 Apr; 61:39-43.
    View in: PubMed
    Score: 0.112
  17. Zangari M, Berno T, Zhan F, Tricot G, Fink L. Mechanisms of thrombosis in paraproteinemias: the effects of immunomodulatory drugs. Semin Thromb Hemost. 2012 Nov; 38(8):768-79.
    View in: PubMed
    Score: 0.103
  18. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.093
  19. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.093
  20. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.093
  21. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.093
  22. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.093
  23. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.093
  24. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.093
  25. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.093
  26. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.093
  27. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.093
  28. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.093
  29. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.093
  30. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.093
  31. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.093
  32. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.093
  33. Zangari M, Tricot G, Polavaram L, Zhan F, Finlayson A, Knight R, Fu T, Weber D, Dimopoulos MA, Niesvizky R, Fink L. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol. 2010 Jan 01; 28(1):132-5.
    View in: PubMed
    Score: 0.084
  34. Tricot G, Zangari M, Sorasio R, Bruno B. Evolving indications for hematopoietic stem cell transplantation in multiple myeloma and other plasma cell disorders. Cancer Treat Res. 2009; 144:317-55.
    View in: PubMed
    Score: 0.079
  35. Talamo G, Claxton D, Tricot G, Fink L, Zangari M. Response to bortezomib in refractory type I cryoglobulinemia. Am J Hematol. 2008 Nov; 83(11):883-4.
    View in: PubMed
    Score: 0.078
  36. Tricot G, Barlogie B, Zangari M, van Rhee F, Hoering A, Szymonifka J, Cottler-Fox M. Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy. Haematologica. 2008 Nov; 93(11):1739-42.
    View in: PubMed
    Score: 0.077
  37. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.075
  38. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.075
  39. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.075
  40. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.075
  41. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.075
  42. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.075
  43. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.075
  44. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.075
  45. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.075
  46. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.075
  47. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.075
  48. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.075
  49. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.075
  50. Talamo G, Cavallo F, Zangari M, Barlogie B, Lee CK, Pineda-Roman M, Kiwan E, Krishna S, Tricot G. Hyperammonemia and encephalopathy in patients with multiple myeloma. Am J Hematol. 2007 May; 82(5):414-5.
    View in: PubMed
    Score: 0.071
  51. Elice F, Fink L, Tricot G, Barlogie B, Zangari M. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol. 2006 Aug; 134(4):399-405.
    View in: PubMed
    Score: 0.067
  52. Barlogie B, Zangari M, Bolejack V, Hollmig K, Anaissie E, van Rhee F, Pineda-Roman M, Mohiuddin A, Crowley J, Tricot G. Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myeloma. Clin Lymphoma Myeloma. 2006 May; 6(6):469-74.
    View in: PubMed
    Score: 0.066
  53. Cheng Y, Sun F, Alapat DV, Wanchai V, Mery D, Siegel ER, Xu H, Johnson S, Guo W, Bailey C, Ashby C, Bauer MA, Hadidi SA, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages. Blood Cancer J. 2024 11 06; 14(1):194.
    View in: PubMed
    Score: 0.060
  54. Al Hadidi S, Ababneh O, Schinke C, Thanendrarajan S, Bailey C, Tricot G, Shaughnessy J, Zhan F, Sawyer J, Siegel ER, Zangari M, Barlogie B, van Rhee F. Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol. 2024 Nov; 99(11):2222-2224.
    View in: PubMed
    Score: 0.058
  55. Guo W, Strouse C, Mery D, Siegel ER, Munshi MN, Ashby TC, Cheng Y, Sun F, Wanchai V, Zhang Z, Bailey C, Alapat DV, Peng H, Al Hadidi S, Thanendrarajan S, Schinke C, Zangari M, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation. Cancers (Basel). 2024 Mar 11; 16(6).
    View in: PubMed
    Score: 0.057
  56. Guo W, Zhan Y, Mery D, Siegel ER, Sun F, Cheng Y, Ashby TC, Zhang Z, Bailey C, Alapat DV, Peng H, Hadidi SA, Thanendrarajan S, Schinke C, Zangari M, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems. Blood Cancer J. 2024 02 14; 14(1):30.
    View in: PubMed
    Score: 0.057
  57. Sun F, Cheng Y, Wanchai V, Guo W, Mery D, Xu H, Gai D, Siegel E, Bailey C, Ashby C, Al Hadidi S, Schinke C, Thanendrarajan S, Ma Y, Yi Q, Orlowski RZ, Zangari M, van Rhee F, Janz S, Bishop G, Tricot G, Shaughnessy JD, Zhan F. Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth. Nat Commun. 2024 Jan 19; 15(1):615.
    View in: PubMed
    Score: 0.056
  58. Sun F, Cheng Y, Chen JR, Wanchai V, Mery DE, Xu H, Gai D, Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions. J Clin Invest. 2024 01 02; 134(1).
    View in: PubMed
    Score: 0.056
  59. Fassas AB, Barlogie B, Ward S, Jagannath S, Vesole D, Mattox S, Siegel D, Muwalla F, Zangari M, Anaissie E, Rhee FV, Thertulien R, Lee CK, Desikan R, Arzumanian V, McCoy J, Tricot G. Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience. Br J Haematol. 2003 Nov; 123(3):484-9.
    View in: PubMed
    Score: 0.055
  60. Cheng Y, Sun F, Alapat DV, Wanchai V, Mery D, Guo W, Cao H, Zhu Y, Ashby C, Bauer MA, Nookaew I, Siegel ER, Ying J, Chen JR, Gai D, Peng B, Xu H, Bailey C, Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, Chesi M, Bergsagel PL, van Rhee F, Janz S, Tricot G, Shaughnessy JD, Zhan F. High NEK2 expression in myeloid progenitors suppresses T?cell immunity in multiple myeloma. Cell Rep Med. 2023 10 17; 4(10):101214.
    View in: PubMed
    Score: 0.055
  61. Sun F, Cheng Y, Ying J, Mery D, Al Hadidi S, Wanchai V, Siegel ER, Xu H, Gai D, Ashby TC, Bailey C, Chen JR, Schinke C, Thanendrarajan S, Zangari M, Janz S, Barlogie B, Van Rhee F, Tricot G, Shaughnessy JD, Zhan F. A gene signature can predict risk of MGUS progressing to multiple myeloma. J Hematol Oncol. 2023 06 29; 16(1):70.
    View in: PubMed
    Score: 0.054
  62. Lee CK, Badros A, Barlogie B, Morris C, Zangari M, Fassas A, van Rhee F, Cottler-Fox M, Jacobson J, Thertulien R, Muwalla F, Mazher S, Anaissie E, Tricot G. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol. 2003 Jan; 31(1):73-80.
    View in: PubMed
    Score: 0.052
  63. Barlogie B, Shaughnessy J, Zangari M, Tricot G. High-dose therapy and immunomodulatory drugs in multiple myeloma. Semin Oncol. 2002 Dec; 29(6 Suppl 17):26-33.
    View in: PubMed
    Score: 0.052
  64. Fassas AB, Spencer T, Desikan R, Zangari M, Anaissie E, Barlogie B, Tricot G. Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients. Br J Haematol. 2002 Oct; 119(1):164-8.
    View in: PubMed
    Score: 0.051
  65. Gai D, Chen JR, Stewart JP, Nookaew I, Habelhah H, Ashby C, Sun F, Cheng Y, Li C, Xu H, Peng B, Garg TK, Schinke C, Thanendrarajan S, Zangari M, Chen F, Barlogie B, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation. J Clin Invest. 2022 09 15; 132(18).
    View in: PubMed
    Score: 0.051
  66. Fassas AB, Spencer T, Sawyer J, Zangari M, Lee CK, Anaissie E, Muwalla F, Morris C, Barlogie B, Tricot G. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol. 2002 Sep; 118(4):1041-7.
    View in: PubMed
    Score: 0.051
  67. Alqazaqi R, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy J, Zhan F, Tricot G, van Rhee F, Al Hadidi S. Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma. JAMA Netw Open. 2022 08 01; 5(8):e2228877.
    View in: PubMed
    Score: 0.051
  68. Badros A, Morris C, Zangari M, Barlogie B, Tricot G. Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia. Leuk Lymphoma. 2002 Jun; 43(6):1267-71.
    View in: PubMed
    Score: 0.050
  69. Fassas AB, Muwalla F, Berryman T, Benramdane R, Joseph L, Anaissie E, Sethi R, Desikan R, Siegel D, Badros A, Toor A, Zangari M, Morris C, Angtuaco E, Mathew S, Wilson C, Hough A, Harik S, Barlogie B, Tricot G. Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. Br J Haematol. 2002 Apr; 117(1):103-8.
    View in: PubMed
    Score: 0.050
  70. Badros A, Barlogie B, Siegel E, Cottler-Fox M, Zangari M, Fassas A, Morris C, Anaissie E, Van Rhee F, Tricot G. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol. 2002 Mar 01; 20(5):1295-303.
    View in: PubMed
    Score: 0.049
  71. Tricot G, Spencer T, Sawyer J, Spoon D, Desikan R, Fassas A, Badros A, Zangari M, Munshi N, Anaissie E, Toor A, Barlogie B. Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br J Haematol. 2002 Jan; 116(1):211-7.
    View in: PubMed
    Score: 0.049
  72. Baker D, Bimali M, Carrillo L, Sachedina A, Alapat D, Hoque MS, Kottarathara M, Parikh R, Erra A, Mitma AA, Mathur P, Ogunsesan Y, Yarlagadda L, Gundarlapalli S, Thanendrarajan S, Zangari M, Van Rhee F, Tricot G, Schinke C. Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica. 2021 08 12.
    View in: PubMed
    Score: 0.048
  73. Yarlagadda L, Gundarlapalli S, Parikh R, Landes RD, Kottarathara M, Ogunsesan Y, Hoque S, Mitma AA, Bailey C, Hill KM, Thanendrarajan S, Graziutti M, Mohan M, Zangari M, van Rhee F, Tricot G, Schinke C. Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma. Cancers (Basel). 2021 Aug 10; 13(16).
    View in: PubMed
    Score: 0.048
  74. Zhou W, Yang Y, Xia J, Wang H, Salama ME, Xiong W, Xu H, Shetty S, Chen T, Zeng Z, Shi L, Zangari M, Miles R, Bearss D, Tricot G, Zhan F. NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer Cell. 2013 Jan 14; 23(1):48-62.
    View in: PubMed
    Score: 0.026
  75. Kim JH, Goulston C, Sanders S, Lampas M, Zangari M, Tricot G, Hanson KE. Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation. Biol Blood Marrow Transplant. 2012 Nov; 18(11):1753-8.
    View in: PubMed
    Score: 0.025
  76. Cruz RD, Tricot G, Zangari M, Zhan F. Progress in myeloma stem cells. Am J Blood Res. 2011; 1(2):135-45.
    View in: PubMed
    Score: 0.024
  77. Wu X, Shi J, Wu Y, Tao Y, Hou J, Meng X, Hu X, Han Y, Jiang W, Tang S, Zangari M, Tricot G, Zhan F. Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2. Cancer Biol Ther. 2010 Dec 01; 10(11):1201-14.
    View in: PubMed
    Score: 0.023
  78. Pineda-Roman M, Barlogie B, Anaissie E, Zangari M, Bolejack V, van Rhee F, Tricot G, Crowley J. High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients. Cancer. 2008 Apr 15; 112(8):1754-64.
    View in: PubMed
    Score: 0.019
  79. Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, Cottler-Fox M, Mohiuddin A, Alsayed Y, Tricot G, Bolejack V, Zangari M, Epstein J, Petty N, Steward D, Jenkins B, Gurley J, Sullivan E, Crowley J, Shaughnessy JD. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol. 2007 Jul; 138(2):176-85.
    View in: PubMed
    Score: 0.018
  80. van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J, Shaughnessy JD, Zangari M, Tricot G, Mohiuddin A, Alsayed Y, Woods G, Crowley J, Barlogie B. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood. 2007 Aug 01; 110(3):827-32.
    View in: PubMed
    Score: 0.018
  81. Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD, Epstein J, van Hemert R, Erdem E, Hoering A, Crowley J, Ferris E, Hollmig K, van Rhee F, Zangari M, Pineda-Roman M, Mohiuddin A, Yaccoby S, Sawyer J, Angtuaco EJ. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol. 2007 Mar 20; 25(9):1121-8.
    View in: PubMed
    Score: 0.017
  82. Shaughnessy JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, Anaissie E, Krishna SG, Cottler-Fox M, Hollmig K, Mohiuddin A, Pineda-Roman M, Tricot G, van Rhee F, Sawyer J, Alsayed Y, Walker R, Zangari M, Crowley J, Barlogie B. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007 Mar 15; 109(6):2276-84.
    View in: PubMed
    Score: 0.017
  83. Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Zangari M, Dhodapkar M, Shaughnessy JD. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood. 2007 Feb 15; 109(4):1692-700.
    View in: PubMed
    Score: 0.017
  84. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, Fassas A, Zangari M, Hollmig K, Pineda-Roman M, Lee C, Talamo G, Thertulien R, Kiwan E, Krishna S, Fox M, Crowley J. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006 Mar 09; 354(10):1021-30.
    View in: PubMed
    Score: 0.016
  85. Yaccoby S, Wezeman MJ, Zangari M, Walker R, Cottler-Fox M, Gaddy D, Ling W, Saha R, Barlogie B, Tricot G, Epstein J. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica. 2006 Feb; 91(2):192-9.
    View in: PubMed
    Score: 0.016
  86. Barlogie B, Tricot G, Rasmussen E, Anaissie E, van Rhee F, Zangari M, Fassas A, Hollmig K, Pineda-Roman M, Shaughnessy J, Epstein J, Crowley J. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood. 2006 Apr 01; 107(7):2633-8.
    View in: PubMed
    Score: 0.016
  87. Talamo G, Angtuaco E, Walker RC, Dong L, Miceli MH, Zangari M, Tricot G, Barlogie B, Anaissie E. Avascular necrosis of femoral and/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy. J Clin Oncol. 2005 Aug 01; 23(22):5217-23.
    View in: PubMed
    Score: 0.016
  88. Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, Walker R, Crowley J. Treatment of multiple myeloma. Blood. 2004 Jan 01; 103(1):20-32.
    View in: PubMed
    Score: 0.014
  89. Jacobson J, Barlogie B, Shaughnessy J, Drach J, Tricot G, Fassas A, Zangari M, Giroux D, Crowley J, Hough A, Sawyer J. MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants. Br J Haematol. 2003 Aug; 122(3):430-40.
    View in: PubMed
    Score: 0.014
  90. Desikan R, Barlogie B, Sethi R, Toor A, Spoon D, Angtuaco E, Vanhemert R, VijayaGopal A, Singhal S, Mehta J, Jagannath S, Munshi N, Zangari M, Fassas A, Tricot G, Anaissie E. Infection--an underappreciated cause of bone pain in multiple myeloma. Br J Haematol. 2003 Mar; 120(6):1047-50.
    View in: PubMed
    Score: 0.013
  91. Shaughnessy J, Tian E, Sawyer J, McCoy J, Tricot G, Jacobson J, Anaissie E, Zangari M, Fassas A, Muwalla F, Morris C, Barlogie B. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br J Haematol. 2003 Jan; 120(1):44-52.
    View in: PubMed
    Score: 0.013
  92. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, van Rhee F, Fassas A, Crowley J, Tricot G, Barlogie B, Shaughnessy J. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002 Mar 01; 99(5):1745-57.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.